MarketPulse

PALISADE-2 trial

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Vistagen Investors Pursue Securities Fraud Claims Over Misleading Drug Trial Statements

Schall Law Firm seeks Vistagen investors in class action over alleged false statements regarding fasedienol drug candidate's Phase 3 trial prospects.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Schall Law Firm Opens Class Action Against Vistagen Over PALISADE-2 Trial Disclosures

Schall Law Firm launches securities fraud class action against Vistagen for allegedly making misleading statements about fasedienol drug trial prospects, affecting investors from April 2024 to December 2025.
VTGNsecurities fraudclass action lawsuit